title: Efficacy of various therapeutic regimens in eliminating Pasteurella pneumotropica from the mouse.
abstract: Pasteurella pneumotropica, a gram-negative opportunistic pathogen, can be isolated from the oropharynx, intestinal tract, and reproductive tract of clinically normal mice and has been associated with various clinical syndromes, including conjunctivitis, infections of the reproductive tract, otitis, and subcutaneous abscess formation. Enrofloxacin, a fluoroquinolone bactericidal antimicrobial, has been shown to be effective in eliminating P. multocida from rabbits. We sought to determine whether enrofloxacin would eliminate P. pneumotropica from mice known to be asymptomatically infected with the agent. Pasteurella pneumotropica-positive (culture and immunofluorescence assay) male (n = 55) and female (n = 55) C57BL/6N mice were randomly assigned to one of seven treatment groups or to a control group. These groups were designed to evaluate the efficacy of enrofloxacin administered orally via the drinking water or parenterally at three dosages (8.5, 25.5, and 85.0 mg/kg of body weight per day) over a 14-day treatment period. A tetracycline-treated group (60 mg/kg per day) and an untreated control group were included for comparisons. Repeated oropharyngeal swab and fecal specimens were obtained for culture through posttreatment day 30, and specimens from numerous enteric and reproductive organs collected during necropsy were used to evaluate group differences. Enrofloxacin eliminated evidence of P. pneumotropica from all sites when administered at 25.5 or 85 mg/kg but not at 8.5 mg/kg by either route for at least 30 days after treatment. Tetracycline-treated and control groups remained consistently culture-positive throughout the study. We concluded that the oral route may be a more practical method for treating large numbers of mice. Enrofloxacin may be a practical and inexpensive alternative to cesarian rederivation or embryo transfer for the elimination of P. pneumotropica in mice.
authors.affiliation: Comparative Medicine Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA.
authors.forename: M F
authors.initials: MF
authors.lastname: Goelz
authors.forename: J E
authors.initials: JE
authors.lastname: Thigpen
authors.forename: J
authors.initials: J
authors.lastname: Mahler
authors.forename: W P
authors.initials: WP
authors.lastname: Rogers
authors.forename: J
authors.initials: J
authors.lastname: Locklear
authors.forename: B J
authors.initials: BJ
authors.lastname: Weigler
authors.forename: D B
authors.initials: DB
authors.lastname: Forsythe
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000077422:Enrofloxacin; D005260:Female; D024841:Fluoroquinolones; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010325:Pasteurella / Q000302:isolation & purification*; D010326:Pasteurella Infections / Q000188:drug therapy / Q000517:prevention & control / Q000662:veterinary*; D015363:Quinolones / Q000627:therapeutic use*; D012376:Rodent Diseases / Q000188:drug therapy* / Q000517:prevention & control; D013752:Tetracycline / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D000077422:Enrofloxacin; D013752:Tetracycline